Hospital
Blue Ridge Healthcare Hospitals, INC.
Blue Ridge Healthcare Hospitals, INC. was paid $20.14M by Medicaid between Jan 2018 and Dec 2024, across 133 billing codes. Its largest line is 99283, emergency room visit (moderate) — 30% of everything it billed.
33Billing provider infoBLUE RIDGE HEALTHCARE HOSPITALS, INC.
MORGANTON, NC 28655
MORGANTON, NC 28655
33aNPI1700860491assigned 12/06/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$20.14M
24GClaims391,683
24DCodes billed133
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#30 of 92
Median peer was paid$11.47M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MOLL, PATRICIA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 46,281 | $1.87M | |
| 2019 | 50,613 | $2.20M | |
| 2020 | 34,031 | $1.54M | |
| 2021 | 45,216 | $2.75M | |
| 2022 | 64,801 | $3.56M | |
| 2023 | 72,595 | $3.94M | |
| 2024incomplete | 78,146 | $4.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 30% | 36,798 | 34,102 | $6.11M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 28% | 29,160 | 26,624 | $5.73M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.4% | 9,152 | 8,352 | $1.88M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 7.2% | 9,201 | 8,314 | $1.45M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.4% | 23,111 | 19,313 | $677K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 813 | 751 | $460K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.2% | 6,202 | 5,815 | $442K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 12,826 | 11,664 | $321K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 37,352 | 32,766 | $279K |
| 80053 | Comprehensive metabolic panel | 1.4% | 32,328 | 28,559 | $277K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 7,947 | 7,095 | $244K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 6,490 | 5,606 | $232K |
121 more codes
| 62323 | <1% | 1,050 | $185K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 108 | $178K |
| J3490 | Unclassified drugs | <1% | 63,932 | $166K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,492 | $107K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,036 | $104K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,061 | $74K |
| 20610 | <1% | 799 | $64K | |
| 81001 | <1% | 17,981 | $60K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,071 | $60K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,538 | $57K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 845 | $57K |
| 87400 | <1% | 4,816 | $53K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,283 | $51K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 322 | $48K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,567 | $47K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 163 | $45K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 677 | $45K |
| 81025 | <1% | 4,329 | $36K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 472 | $34K |
| 83690 | <1% | 4,664 | $33K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,912 | $30K |
| G0378 | Hospital observation service, per hour | <1% | 276 | $27K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 794 | $27K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 574 | $25K |
| 84484 | <1% | 2,842 | $24K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,835 | $22K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 263 | $22K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 48 | $22K |
| 20553 | <1% | 163 | $17K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 57 | $16K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,350 | $15K |
| 83605 | <1% | 1,084 | $14K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 111 | $13K |
| 80061 | Lipid panel | <1% | 863 | $13K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,711 | $12K |
| 83735 | <1% | 1,957 | $12K | |
| 59025 | Fetal non-stress test | <1% | 145 | $11K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,197 | $11K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 166 | $11K |
| 62321 | <1% | 27 | $10K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 346 | $10K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,071 | $9K |
| 87081 | <1% | 914 | $9K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,321 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 767 | $8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 393 | $8K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,921 | $8K |
| 27096 | <1% | 133 | $8K | |
| 74018 | <1% | 186 | $7K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,871 | $7K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 2,390 | $6K |
| 81003 | <1% | 1,295 | $5K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 976 | $5K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,769 | $5K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,090 | $5K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,858 | $5K |
| 72141 | <1% | 30 | $5K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,942 | $5K |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 2,453 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 200 | $4K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,861 | $4K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 97 | $4K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,099 | $4K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 219 | $3K |
| 87420 | <1% | 169 | $2K | |
| 97597 | <1% | 41 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 746 | $2K |
| 85027 | <1% | 309 | $2K | |
| 77336 | <1% | 25 | $1K | |
| 96415 | <1% | 38 | $1K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 13 | $1K |
| 85610 | <1% | 364 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,261 | $1K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 671 | $1K |
| 80320 | <1% | 80 | $1K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 294 | $1K |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 226 | $1K |
| 83880 | <1% | 38 | $951.48 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 394 | $913.14 |
| 76942 | <1% | 13 | $893.09 | |
| 82962 | <1% | 681 | $885.01 | |
| 80329 | <1% | 15 | $761.33 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 128 | $743.62 |
| 87040 | <1% | 30 | $606.77 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 168 | $566.43 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 200 | $549.62 |
| 71271 | <1% | 13 | $453.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 69 | $400.89 |
| 81015 | <1% | 81 | $395.29 | |
| 82728 | <1% | 27 | $365.73 | |
| 96376 | <1% | 16 | $331.86 | |
| Q3014 | Telehealth originating site facility fee | <1% | 38 | $315.29 |
| 94760 | <1% | 246 | $298.47 | |
| G0238 | Therapeutic procedures to improve respiratory function, other than described by g0237, one on one, face to face, per 15 minutes (includes monitoring) | <1% | 15 | $254.98 |
| 90715 | <1% | 19 | $243.51 | |
| 83550 | <1% | 26 | $234.69 | |
| 83540 | <1% | 26 | $174.17 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 19 | $158.67 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 84 | $158.20 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 157 | $148.93 |
| 82550 | <1% | 18 | $145.73 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 69 | $128.93 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 15 | $125.57 |
| 84439 | <1% | 12 | $107.69 | |
| 85730 | <1% | 16 | $66.57 | |
| 82948 | <1% | 38 | $65.31 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 82 | $57.28 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 15 | $54.80 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 27 | $46.58 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 14 | $44.80 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 13 | $43.27 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 241 | $38.13 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 12 | $34.87 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 12 | $31.83 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 16 | $30.50 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 14 | $22.98 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 28 | $17.73 |
| 85018 | <1% | 23 | $5.90 | |
| A9270 | Non-covered item or service | <1% | 1,417 | $1.75 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 430 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 268 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMOLL, PATRICIA (CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.